Table 5 Comparison of clinical features 6 h after the start of PMX-DHP between survivors and non-survivors
Survivors ( n = 23) | Non-survivors ( n = 6) | P values | |
|---|---|---|---|
MAP (mmHg) | 75 (45–101) | 79 (42–98) | 0.914 |
VDI (/mmHg) | 0.106 (0.000–0.569) | 0.256 (0.130–0.612) | 0.076 |
Improvement rate of VDI (%) | 39.3 (−116.9–100.0) | 39.2 (−61.4–74.1) | 0.957 |
Leukocytes (/μl) | 5,700 (1,050–31,200) | 3,800 (1,400–11,100) | 0.200 |
Arterial blood gas | |||
pH | 7.395 (7.305–7.458) | 7.329 (7.130–7.388) | 0.018 |
Base excess (mmol/l) | −1.7 (−6.7–5.5) | −7.2 (−12.9–0.2) | 0.007 |
P/F (mmHg) | 267 (108–483) | 222 (50–379) | 0.132 |
Improvement rate of P/F (%) | 9.0 (−44.8–228.2) | 59.2 (−76.5–169.8) | 0.518 |
Lactate (mmol/l) | 2.9 (0.8–8.8) | 6.5 (1.3–9.9) | 0.043 |
Lactate clearance (%) | 10.0 (−83.3–61.9) | −6.6 (−65.0–23.5) | 0.060 |